<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107207</article-id><article-id pub-id-type="publisher-id">ACM-36604</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_11249679.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新辅助化疗治疗进展期胃癌的疗效分析
  The Efficacy Analysis in the Treatment of Advanced Gastric Cancer with Neoadjuvant Chemotherapy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>辉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孟</surname><given-names>松</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>立彬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>洪</surname><given-names>健</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邵</surname><given-names>永</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>孝成</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>徐州医科大学附属医院胃肠外科，江苏 徐州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1376</fpage><lpage>1382</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨进展期胃癌应用新辅助化疗的疗效及其安全性。方法：回顾性分析2013年1月至2019年2月间我收治的56例进展期胃癌患者临床资料，采用新辅助化疗，2个治疗周期后进行化疗疗效分析；并评估临床疗效和不良反应。结果：所有患者均顺利完成新辅助化疗(100%)，平均化疗周期为2.48 &#177; 0.15个周期，化疗方案有SOX方案、DOS方案和FLOT方案。本组病例中CR 3例(5.35%)，PR 30例(53.57%)，SD 15例(26.79%)，PD 8例(14.29%)，有效率58.93%。49例行根治性切除术，4例行姑息性切除术，3例因疾病进展未进行手术。化疗副反应主要有骨髓抑制、恶心呕吐、腹泻、肝功能损害、皮肤过敏。中位存活时间为23.5个月。结论：新辅助化疗疗效安全、副反应低，能给部分进展期胃癌患者带来生存获益。
    Objective: To investigate the efficacy and safety of neoadjuvant chemotherapy for advanced gastric cancer. Methods: From January 2013 to February 2019, 56 patients with advanced gastric cancer who treated with neoadjuvant chemotherapy were retrospectively analyzed. The efficacy of chemotherapy was analyzed after 2 treatment cycles. Clinical efficacy and adverse reactions were evaluated. Results: All patients successfully completed neoadjuvant chemotherapy (100%) with an average chemotherapy cycle of 2.48 &#177; 0.15 cycles. The chemotherapy regimen included SOX regimen, DOS regimen and FLOT regimen. In this group, there were 3 cases of CR (5.35%), 30 cases of PR (53.57%), 15 cases of SD (26.79%), and 8 cases of PD (14.29%), with an effective rate of 58.93%. Forty-nine patients underwent radical resection, 4 underwent palliative resection, and 3 did not undergo surgery due to disease progression. The Side effects of chemotherapy mainly include myelosuppression, nausea and vomiting, diarrhea, liver damage, skin allergy. Median survival was 23.5 months. Conclusion: Neoadjuvant chemotherapy is safe and has low side effects. It can bring survival benefit to some patients with advanced gastric cancer. 
  
 
</p></abstract><kwd-group><kwd>胃癌，新辅助化疗，不良反应，病理完全缓解, Gastric Cancer</kwd><kwd> Neoadjuvant Chemotherapy</kwd><kwd> Adverse Reactions</kwd><kwd> Pathological Complete Response</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>新辅助化疗治疗进展期胃癌的疗效分析<sup> </sup></title><p>王辉，李超，孟松，姚立彬，洪健，邵永，朱孝成<sup>*</sup></p><p>徐州医科大学附属医院胃肠外科，江苏 徐州</p><p>收稿日期：2020年7月1日；录用日期：2020年7月14日；发布日期：2020年7月21日</p><disp-formula id="hanspub.36604-formula22"><graphic xlink:href="//html.hanspub.org/file/33-1571387x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨进展期胃癌应用新辅助化疗的疗效及其安全性。方法：回顾性分析2013年1月至2019年2月间我收治的56例进展期胃癌患者临床资料，采用新辅助化疗，2个治疗周期后进行化疗疗效分析；并评估临床疗效和不良反应。结果：所有患者均顺利完成新辅助化疗(100%)，平均化疗周期为2.48 &#177; 0.15个周期，化疗方案有SOX方案、DOS方案和FLOT方案。本组病例中CR 3例(5.35%)，PR 30例(53.57%)，SD 15例(26.79%)，PD 8例(14.29%)，有效率58.93%。49例行根治性切除术，4例行姑息性切除术，3例因疾病进展未进行手术。化疗副反应主要有骨髓抑制、恶心呕吐、腹泻、肝功能损害、皮肤过敏。中位存活时间为23.5个月。结论：新辅助化疗疗效安全、副反应低，能给部分进展期胃癌患者带来生存获益。</p><p>关键词 :胃癌，新辅助化疗，不良反应，病理完全缓解</p><disp-formula id="hanspub.36604-formula23"><graphic xlink:href="//html.hanspub.org/file/33-1571387x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/33-1571387x8_hanspub.png" /> <img src="//html.hanspub.org/file/33-1571387x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>胃癌是常见的恶性肿瘤之一。在我国，虽然胃癌的总体发病率在下降，但仍居中国所有恶性肿瘤的第二位 [<xref ref-type="bibr" rid="hanspub.36604-ref1">1</xref>]。根治性切除是胃癌治疗的主要方法。由于筛查和早期诊断的困难，中国约80%的胃癌患者在首次就诊时已处于进展期 [<xref ref-type="bibr" rid="hanspub.36604-ref2">2</xref>]，5年生存率仅为20%~30% [<xref ref-type="bibr" rid="hanspub.36604-ref3">3</xref>]。在MAGIC [<xref ref-type="bibr" rid="hanspub.36604-ref4">4</xref>] 和FNCLCCFFCD [<xref ref-type="bibr" rid="hanspub.36604-ref5">5</xref>] 试验的结果发表后，新辅助化疗受到越来越多临床医生的重视，该文旨在探讨进展期胃癌应用新辅助化疗的疗效及其安全性。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>病例纳入标准：1) 胃镜病理证实为胃癌(包括贲门癌和胃食管结合部癌)；2) CT显示肿瘤侵犯胃壁全层(T3或T4)或有区域淋巴结肿大或有临近脏器侵袭转移(肝脏)；3) 所有患者体力状况(ECOG)评分为0~2分，无严重心、肺、肝、肾等脏器功能异常者；4) 既往无其他肿瘤病史，未接受过放疗、化疗者；5) 签署化疗知情同意书，愿意接受术前新辅助化疗。按上述入组标准，2013年1月至2019年2月间我院收治的56例局部进展期胃癌患者纳入本研究，其中男性47例，女性9例。年龄30~81岁，平均年龄60.86 &#177; 1.50岁。病变部位：胃食管结合部5例，贲门18例，胃体10例，胃窦20例，贲门–胃体–胃窦3例。肿瘤分期采用第8版美国癌症联合委员(AJCC) TNM分期 [<xref ref-type="bibr" rid="hanspub.36604-ref6">6</xref>]，本组病例IIIA期13例，IIIB期18例，IIIC期15例，IV期10例。该研究获得我院伦理审批许可。</p></sec><sec id="s4_2"><title>2.2. 研究方法</title><sec id="s4_2_1"><title>2.2.1. 化疗方案</title><p>1) SOX方案：奥沙利铂130 mg/m<sup>2</sup>静脉滴注d1；替吉奥40 mg/m<sup>2</sup>口服bid d1-14，21天为1疗程。2) DOS方案：多西他赛60 mg/m<sup>2</sup>，静脉滴注d1，奥沙利铂100 mg/m<sup>2</sup>，静脉滴注d2，替吉奥40 mg/m<sup>2</sup>口服bid d1-14，每21 d为一疗程。3) FLOT方案：多西他赛60 mg/m<sup>2</sup>静脉滴注d1，奥沙利铂130 mg/m<sup>2</sup>静脉滴注d1，亚叶酸钙200 mg/m<sup>2</sup>静脉滴注d1，氟尿嘧啶2600 mg/m<sup>2</sup> 24 h持续静脉滴注d1，14 d为1疗程。2疗程结束后3周复查腹部增强CT，评估化疗效果及身体情况。</p></sec><sec id="s4_2_2"><title>2.2.2. 手术方式</title><p>2~8周期化疗结束3周后按照日本胃癌协会《胃癌治疗指南》(第3版) [<xref ref-type="bibr" rid="hanspub.36604-ref7">7</xref>] 规定行手术治疗。首选根治性切除术，若局部肿瘤无法完整切除，则选择姑息性切除。</p></sec></sec><sec id="s4_3"><title>2.3. 观察指标及评定标准</title><sec id="s4_3_1"><title>2.3.1. 化疗疗效评价</title><p>根据原发实体瘤的疗效评价标准(RECIST) 1.1判定疗效，分为完全缓解(Complete Response, CR)、部分缓解(Partial Response, PR)、病情稳定(Stable Disease, SD)、病情进展(Progressive Disease, PD) 4种。指所有病灶消失，任何病理性淋巴结(无论是否为目标病灶)的短轴值小于10 mm；PR指所有目标病灶直径的总和减小大于30%；SD指基线病灶有缩小，但未达到PR标准，有增加也未达到PD标准；SD指基线病灶有缩小，但未达到PR标准，有增加也未达到PD标准 [<xref ref-type="bibr" rid="hanspub.36604-ref8">8</xref>]。有效率 = (CR + PR)例数/总例数。</p></sec><sec id="s4_3_2"><title>2.3.2. 化疗毒副反应</title><p>化疗期间定期复查血常规、肝肾功能。化疗毒性反应按照1997年WHO抗癌药物常见毒副反应分级标准进行分级。</p></sec></sec><sec id="s4_4"><title>2.4. 术后随访</title><p>随访采用住院复查、门诊随访和电话随访。随访终止日期为2019年11月25日。</p></sec><sec id="s4_5"><title>2.5. 统计学方法</title><p>采用SPSS24.0统计软件分析。数据均以均数 &#177; 标准差( x &#175; &#177; s)表示。采用生存分析法分析中位生存时间。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 化疗疗效评价</title><p>所有患者均完成化疗，平均化疗周期为2.48 &#177; 0.15个周期。本组病例中CR3例(5.35%)，PR 30例(53.57%)，SD 15例(26.79%)，PD 8例(14.29%)，有效率58.93%。</p></sec><sec id="s5_2"><title>3.2. 手术</title><p>本组病例中，49例行根治性切除术，其中腹腔镜辅助下根治手术17例，胃癌根治术28例，D2+根治手术4例，手术根治切除率达87.50%。4例行姑息性切除术，其中2例因肿瘤进展导致贲门/幽门梗阻，另2例肝转移仅行原发灶切除。3例因疾病进展未进行手术，其中1例骨转移，1例肝脏多发转移，1例大网膜多发种植转移。</p></sec><sec id="s5_3"><title>3.3. 毒副反应</title><p>骨髓抑制主要以血小板和白细胞减少为主，I级白细胞减少3例，II级白细胞减少4例，I级血小板减少5例；消化道反应主要为恶心呕吐和腹泻，I级恶心呕吐6例，II级恶心呕吐5例，II级腹泻1例，III级腹泻1例；肝功能损害I级者9例，II度者2例。I级皮肤过敏1例。以上毒副反应经对症治疗后均能按时完成化疗周期，未出现化疗相关死亡病例(见表1)。</p></sec><sec id="s5_4"><title>3.4. 3例病理完全缓解(Pathological Complete Response, PCR)</title><p>本组有3例患者达到PCR (详见表2)，其中胃窦癌2例，贲门癌1例；2例行SOX方案新辅助化疗，1例行FLOT方案新辅助化疗；3例患者均行根治性切除术，目前均存活。</p></sec><sec id="s5_5"><title>3.5. 随访结果</title><p>所有患者均获得随访，随访时间6~76月，中位随访时间19.5月，27例患者因复发转移死亡，中位存活时间为23.5个月(见图1)。8例新辅助化疗进展患者，中位存活时间仅为8个月(见图2)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The occurrence of toxic and side effects of neoadjuvant chemotherap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >毒性反应</th><th align="center" valign="middle" >I级</th><th align="center" valign="middle" >II级</th><th align="center" valign="middle" >III级</th><th align="center" valign="middle" >IV级</th></tr></thead><tr><td align="center" valign="middle" >白细胞减少 血小板减少 恶心呕吐 腹泻 肝功能损害 肾功能损害 皮肤过敏</td><td align="center" valign="middle" >3 5 6 0 9 1 1</td><td align="center" valign="middle" >4 0 5 1 2 0 0</td><td align="center" valign="middle" >0 1 1 1 0 0 0</td><td align="center" valign="middle" >0 0 0 0 0 0 0</td></tr></tbody></table></table-wrap><p>表1. 新辅助化疗毒副反应发生情况</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The clinical medical records of 3 cases with pC</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >编号</th><th align="center" valign="middle" >性别</th><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >肿瘤位置</th><th align="center" valign="middle" >方案</th><th align="center" valign="middle" >周期</th><th align="center" valign="middle" >手术</th><th align="center" valign="middle" >随访(月)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >女</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >贲门</td><td align="center" valign="middle" >SOX</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >根治性全胃切除术</td><td align="center" valign="middle" >59</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >女</td><td align="center" valign="middle" >59</td><td align="center" valign="middle" >胃窦</td><td align="center" valign="middle" >SOX</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >腹腔镜下根治性远端胃切除术</td><td align="center" valign="middle" >29</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >胃窦</td><td align="center" valign="middle" >FLOT</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >根治性远端胃切除术</td><td align="center" valign="middle" >21</td></tr></tbody></table></table-wrap><p>表2. 3例pCR患者的病例资料</p><p>图1. 56例患者生存时间</p><p>图2. 8例新辅助化疗进展患者生存时间</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>肿瘤的复发和转移仍然是导致胃癌患者死亡的主要原因。提高R0切除率，降低复发与转移成为治疗的主要目标。而新辅助化疗有望实现这一目标。对进展期胃癌患者进行新辅助化疗有许多好处：1) 肿瘤的降期，这将有助于进行R0切除。这一点对局部进展期大体积肿瘤尤其重要，因为根治性切除难以进行。2) 新辅助化疗可以杀灭微转移灶，降低术后复发率。3) 新辅助化疗提供最大限度的全身治疗的最佳机会，因为一些患者可能由于手术后恢复延迟而无法完成辅助化疗。</p><p>多项研究发现，新辅助化疗可以带来生存获益 [<xref ref-type="bibr" rid="hanspub.36604-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.36604-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.36604-ref11">11</xref>]。新辅助化疗可以使肿瘤降期，甚至达到PCR。新辅助化疗后获得PCR的可切除胃癌预后优于未获得PCR的患者。但是，病理完全缓解并不等于治愈。一项研究发现，获得PCR的患者的5年总生存率和无复发生存率分别为91%和75% [<xref ref-type="bibr" rid="hanspub.36604-ref12">12</xref>]。也就是说，获得PCR的患者术后也存在转移复发可能，所以术后的辅助化疗和定期随访非常重要。本组3例PCR患者随访时间21~59月，均存活，高于本组患者的中位存活时间，提示PCR患者预后较好。</p><p>肿瘤在新辅助化疗期间可能发生疾病进展的风险，发生率约15% [<xref ref-type="bibr" rid="hanspub.36604-ref13">13</xref>]。对于新辅助治疗期间病情进展的患者，由于术前治疗无效而错过了治愈治疗的机会。也有观点认为，新辅助治疗期间的进展表明了侵袭性较高的肿瘤生物学行为。患有这种恶性肿瘤的患者不适合手术，因此可避免无效的手术。2019年CSCO指南建议如果新辅助治疗后病情进展，如果可以进行R0切除，则应考虑手术治疗。反之，应通过MDT讨论决定下一步治疗方案。本组病例中，疾病进展率为14.9%，与文献报道相符。本组进展病例中位生存时间仅为8个月，即使手术，预后仍较差。笔者认为对于进展病例，应考虑MDT讨论，制定下一步治疗方案。</p><p>目前，对于局部进展期胃癌患者，尚无统一的新辅助化疗方案。Kondo等 [<xref ref-type="bibr" rid="hanspub.36604-ref14">14</xref>] 研究发现，SOX方案是安全有效的新辅助化疗方案，PCR率高，无严重毒副反应。而Wang等 [<xref ref-type="bibr" rid="hanspub.36604-ref15">15</xref>] 发现对于局部进展期胃癌患者，DOS方案比XELOX方案术前化疗获益更大，且无任何附加毒副作用。一项德国的随机对照2/3期试验发现，FLOT (氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛)方案新辅助化疗疗效优于ECF/ECX (表柔比星、顺铂和氟尿嘧啶/卡培他滨)方案，中位生存时间分别为50月和35月 [<xref ref-type="bibr" rid="hanspub.36604-ref16">16</xref>]。笔者认为新辅助化疗方案的选择应综合考虑患者的身体条件、肿瘤分期和病理类型等。</p><p>胃癌化疗周期目前也无统一标准，MAGIC研究中化疗受益的3个周期，而日本研究新辅助化疗多为2个周期。本组病例中平均化疗周期为2.48 &#177; 0.15，笔者认为可R0切除的肿瘤应尽早手术，不能因追求pCR而延长化疗周期，以免因继续化疗后疾病进展而丧失手术机会，临床缓解和R0切除可以改善预后。</p><p>为了提高新辅助化疗的有效率，可以做一些病理学检查和基因检测。比如微卫星不稳定(microsatellite instability, MSI)，研究发现，MSI-H可切除进展期胃癌患者并不能从新辅助化疗获益 [<xref ref-type="bibr" rid="hanspub.36604-ref17">17</xref>]。对于MSI-H患者不考虑术前新辅助化疗。还可以做Her-2检测，Her-2阴性患者使用含铂类药物(顺铂或奥沙利铂)和氟嘧啶类药物(5-氟尿嘧啶或卡培他滨)的方案，Her-2阳性者可联合曲妥单抗、铂类药物和氟嘧啶类药物 [<xref ref-type="bibr" rid="hanspub.36604-ref18">18</xref>]。Lauren分型对于新辅助化疗方案的选择也有参考价值，对于弥漫性型进展期胃癌患者，采用SOX方案，可能生存时间更长 [<xref ref-type="bibr" rid="hanspub.36604-ref19">19</xref>]。</p><p>总之，胃癌新辅助化疗安全、副反应低，能给部分进展期胃癌患者带来生存获益，但是关于标准化疗方案、化疗周期等问题，仍有待进一步研究。</p></sec><sec id="s7"><title>文章引用</title><p>王 辉,李 超,孟 松,姚立彬,洪 健,邵 永,朱孝成. 新辅助化疗治疗进展期胃癌的疗效分析The Efficacy Analysis in the Treatment of Advanced Gastric Cancer with Neoadjuvant Chemotherapy[J]. 临床医学进展, 2020, 10(07): 1376-1382. https://doi.org/10.12677/ACM.2020.107207</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36604-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Sun, K., Zheng, R., et al. (2018) Cancer Incidence and Mortality in China, 2014. Chinese Journal of Cancer Research, 30, 1-12. &lt;br&gt;https://doi.org/10.21147/j.issn.1000-9604.2018.01.01</mixed-citation></ref><ref id="hanspub.36604-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Li, Z., Shan, F., Ying, X., et al. (2018) Laparoscopic or Open Distal Gastrectomy after Neoadjuvant Chemotherapy for Advanced Gastric Cancer: Study Protocol for a Randomised Phase II Trial. BMJ Open, 8, e021633.  
&lt;br&gt;https://doi.org/10.1136/bmjopen-2018-021633</mixed-citation></ref><ref id="hanspub.36604-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Patel, S.H. and Kooby, D.A. (2011) Gastric Adenocarcinoma Surgery and Adjuvant Therapy. Surgical Clinics of North America, 91, 1039-1077. &lt;br&gt;https://doi.org/10.1016/j.suc.2011.06.009</mixed-citation></ref><ref id="hanspub.36604-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa055531</mixed-citation></ref><ref id="hanspub.36604-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ychou, M., Boige, V., Pignon, J.P., et al. (2011) Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. &lt;br&gt;https://doi.org/10.1200/JCO.2010.33.0597</mixed-citation></ref><ref id="hanspub.36604-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">郗洪庆, 张珂诚, 卫勃, 等. 胃癌TNM分期第八版更新在临床诊断治疗中的意义和思考[J]. 中华胃肠外科杂志, 2017, 20(2): 166-170.</mixed-citation></ref><ref id="hanspub.36604-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Japanese Gastric Cancer Association (2011) Japanese Classification of Gastric Carcinoma: 3rd English Edition. Gastric Cancer, 14, 101-112. &lt;br&gt;https://doi.org/10.1007/s10120-011-0041-5</mixed-citation></ref><ref id="hanspub.36604-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al. (2016) RECIST 1.1-Update and Clarification: From the RECIST Committee. European Journal of Cancer, 62, 132-137. &lt;br&gt;https://doi.org/10.1016/j.ejca.2016.03.081</mixed-citation></ref><ref id="hanspub.36604-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Y., Hu, D., Li, W. and Yu, X. (2019) Neoadjuvant Chemotherapy Brings More Survival Benefits than Postoperative Chemotherapy for Resectable Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. JBUON, 24, 201-214.</mixed-citation></ref><ref id="hanspub.36604-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Das, M. (2017) Neoadjuvant Chemotherapy: Survival Benefit in Gastric Cancer. The Lancet Oncology, 18, e307.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(17)30321-2</mixed-citation></ref><ref id="hanspub.36604-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Eom, B.W., Kim, S., Kim, J.Y., et al. (2018) Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. Journal of Gastric Cancer, 18, 69-81.  
&lt;br&gt;https://doi.org/10.5230/jgc.2018.18.e9</mixed-citation></ref><ref id="hanspub.36604-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cho, H., Nakamura, J., Asaumi, Y., et al. (2015) Long-Term Survival Outcomes of Advanced Gastric Cancer Patients Who Achieved a Pathological Complete Response with Neoadjuvant Chemotherapy: A Systematic Review of the Literature. Annals of Surgical Oncology, 22, 787-792. &lt;br&gt;https://doi.org/10.1245/s10434-014-4084-9</mixed-citation></ref><ref id="hanspub.36604-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Fujitani, K., Ajani, J.A., Crane, C.H., et al. (2007) Impact of Induction Chemotherapy and Properative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Annals of Surgical Oncology, 14, 2010-2017. &lt;br&gt;https://doi.org/10.1245/s10434-006-9198-2</mixed-citation></ref><ref id="hanspub.36604-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kondo, K., Matsusaka, S., Ishihara, S., et al. (2019) Long-Term Results of a Multicenter Phase II Study of Preoperative Chemoradiotherapy with S-1 plus Oxaliplatin for Locally Advanced Rectal Cancer (JACCRO CC-04): SHOGUN Trial). Radiotherapy &amp; Oncology, 134, 199-203. &lt;br&gt;https://doi.org/10.1016/j.radonc.2019.02.006</mixed-citation></ref><ref id="hanspub.36604-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Cheng, X., Cui, Y.H., et al. (2018) Efficacy after Preoperative Capecitabine and Oxaliplatin (XELOX) versus Docetaxel, Oxaliplatin and S1 (DOS) in Patients with Locally Advanced Gastric Adenocarcinoma: A Propensity Score Matching Analysis. BMC Cancer, 18, 702. &lt;br&gt;https://doi.org/10.1186/s12885-017-3767-6</mixed-citation></ref><ref id="hanspub.36604-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Al-Batran, S.E., Homann, N., Pauligk, C., et al. (2019) Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. The Lancet, 393, 1948-1957. &lt;br&gt;https://doi.org/10.1016/S0140-6736(18)32557-1</mixed-citation></ref><ref id="hanspub.36604-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Pietrantonio, F., Miceli, R., Raimondi, A., et al. (2019) Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability as a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 37, 3392-3400.  
&lt;br&gt;https://doi.org/10.1200/JCO.19.01124</mixed-citation></ref><ref id="hanspub.36604-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Biagioni, A., Skalamera, I., Peri, S., et al. (2019) Update on Gastric Cancer Treatments and Gene Therapies. Cancer and Metastasis Reviews, 38, 537-548. &lt;br&gt;https://doi.org/10.1007/s10555-019-09803-7</mixed-citation></ref><ref id="hanspub.36604-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Xue, K., Ying, X., Bu, Z., et al. (2018) Oxaliplatin plus S-1 or Capecitabine as Neoadjuvant or Adjuvant Chemotherapy for Locally Advanced Gastric Cancer with D2 Lymphadenectomy: 5-Year Follow-Up Results of a Phase II-III Randomized Trial. Chinese Journal of Cancer Research, 30, 516-525.  
&lt;br&gt;https://doi.org/10.21147/j.issn.1000-9604.2018.05.05</mixed-citation></ref></ref-list></back></article>